Mizuho raises Henry Schein stock target to $78, keeps neutral stance
Securities updated their financial outlook on Henry Schein (NASDAQ:HSIC), increasing the price target to $78 from the previous $75, while maintaining a Neutral rating on the company's stock. According ...
Health Care Down Amid Mixed Earnings -- Health Care Roundup
Health-care companies fell amid mixed earnings. Shares of Danaher, which makes tools and equipment for the biotech, life-sciences and diagnostics businesses, plunged by roughly 10% after it posted ...
KKR builds stake in Henry Schein, agrees deal for board seats, WSJ reports
KKR plans to announce a deal that includes increasing its stake to 12% with the option to buy up to an additional 2.9% in the ...
KKR takes stake in Henry Schein, to take two board seats, WSJ reports
KKR (KKR) has taken a large stake in Henry Schein (HSIC) and plans to announce a deal that includes increasing that stake to 12% with the ...
KKR Builds Stake in Medical-Supply Company, Reaches Deal for Board Seats
KKR has amassed a large stake in the company and plans to announce a deal that includes increasing that stake to 12% with the ...